Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of human dendritic cells cultured with PSAB-liposomes and/or Liraglutide

ABSTRACT: RNA-seq of human dendritic cells cultured with PSAB-liposomes and/or Liraglutide

PROVIDER: PRJNA603462 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10973972_1.fastq.gz	Fastqsanger.gz
	SRR10973972_2.fastq.gz	Fastqsanger.gz
	SRR10973973_1.fastq.gz	Fastqsanger.gz
	SRR10973973_2.fastq.gz	Fastqsanger.gz
	SRR10973974_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

RNA-seq of human dendritic cells cultured with PSAB-liposomes and/or Liraglutide

Project description:RNA-seq data of monocyte-derived human Dendritic cells (huDCs) cultured with PSAB-liposomes and/or Liraglutide

2020-11-12 | GSE144348 | GEO

RNA-Seq analysis on the liver of mice treated with high-fat diet and liraglutide

Project description:GLP-1 based diabetes drugs are effective to reduce hepatic lipid accumulation beyong glycemic control. As GLP-1 receptor (GLP-1R) is not expressed in hepatocytes, the mechanism behind the beneficial effects of GLP-1 based drugs on the liver remained elusive. Several studies have shown that the expression of hepatic fibroblast growth factor 21 (FGF21) can be stimulated by GLP-1-based drugs. Therefore, the present study aimed to assess such stimulation in mice and in mouse primary hepatocytes, determine whether hepatic FGF21 mediates functions of the GLP-1R agonist liraglutide, and to explore the potential mechanisms of liraglutide regulating the expression of FGF21. In high-fat diet induced obese mice, we observed hepatic and plasma FGF21 elevation, improved glucose disposal, and reduced plasma triglyceride levels by liraglutide treatment. Moreover, RNA-sequencing on the liver suggested that Fgf21 was the most upregulated gene after liraglutide treatment. In liver-specific FGF21 knock-out mice on high-fat and high-fructose diet, the body-weight gain attenuation and lipid homeostatic effects of liraglutide was lost or significantly reduced. These studies implied that hepatic FGF21 was the critical mediator of liraglutide-induced metabolic improvement.

2021-03-16 | GSE168937 | GEO

miRNA expression alterations in liraglutide treated rats arota

Project description:liraglutide may distrub miRNA expression in diabetic rats arota

2019-02-11 | GSE102198 | GEO

Gene expression alternations in liraglutide treated rats cardiac muscle

Project description:Diabetic rats changes gene exprssion in liraglutide treated rats cardiac muscle

2018-03-28 | GSE102194 | GEO

Pharmacodynamic effects of GLP-1 agonist liraglutide in adolescent, prediabetic pigs

Project description:GLP-1 agonists are potent glucose-lowering agents, however, their effect on adolescent organisms needs to be clarified Transgenic pigs expressing a dominant-negative GLP receptor randomly assigned for a 90 day treatment trial with liraglutide (0.6-1.8 mg per day)/placebo

2015-12-31 | E-GEOD-56427 | biostudies-arrayexpress

Liraglutide effect on STZ Mouse Kidney with diabetic nephropathy

Project description:The effect of liraglutide on the kidney proteome in the STZ mouse model compared to healthy and STZ diabetic control groups.

2019-01-18 | PXD003007 | Pride

Gene expression data from lung 1 day after influenza infection with liraglutide

Project description:We found liraglutide ameliorates influenza virus infection in mice.Using a microarray, we identified a group of up-regulated genes that could explain influenza improvement.

2020-11-05 | GSE151886 | GEO

Liraglutide inhibits osteoclastogenesis and improves bone loss by down-regulating Trem2 in female type 1 diabetic mice: findings from transcriptomics

Project description:Aims:We aimed to explore possible mechanisms of bone loss in T1D and clarify whether liraglutide have effects on bone quality of T1D mice using transcriptomics, . Methods:Female streptozotocin-induced diabetic C57BL/6J mice were randomly divided into 4 groups and received the following treatments daily for 8 weeks: saline as controls; insulin; liraglutide; liraglutide combined with insulin. These groups were also compared to non-STZ-treated normal glucose tolerance (NGT) group. Trunk blood and bone tissues were collected for analysis. Three tibia from each of the NGT, saline treated and liraglutide treated group were randomly selected for transcriptomics. Results:Compared with NGT mice,saline treated T1D mice manifested markedly hyperglycemia and weight loss, and micro-CT revealed significantly lower bone mineral density(BMD) and deficient microarchitectures in tibias.8 weeks’ treatment with liraglutide alone or combined with insulin rescued the decreased BMD and partly corrected compromised trabecular microarchitectures. Transcriptomics analysis showed there were 789 differentially expressed genes mainly mapped to osteoclastogenesis and inflammation pathways.RT-qPCR verified gene expression of Trem2, Nfatc1, Trap and Ctsk were significantly increased in tibia of T1D compared to that in NGT group. Liraglutide treatment alone or combined with insulin could effectively suppress osteoclastogenesis by down-regulating gene expression of Trem2, Nfatc1, Ctsk and Trap.

2021-11-21 | GSE189112 | GEO

The role of CD11c in dendritic cells

Project description:We cultured bone marrow derived dendritic cells from WT and CD11c KO mice. Then, a group of bone marrow dendritic cells were stimulated with LPS overnight. We obtained bone marrow derived dendritic cells with or without LPS stimulation and analyzed proteomics profiles.

2024-01-26 | PXD048907 |

Transcription profiling by array of human dendritic cells co-cultured with carcinoma cells or treated with lipopolysaccharide

Project description:Human dendritic cells were co-cultured with carcinoma cells (A549 or SK-MES-1) or were treated with lipopolysaccharide (LPS).<br>There were three biological replicates of each condition plus untreated controls giving 12 samples and microarrays in total.<br>Samples were processed with standard Affymetrix IVT protocols and hybridised to Affymetrix Human Genome U133 GeneChips. Data were processed in Bioconductor using RMA.

2009-02-27 | E-MEXP-1958 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data